DBV TECHNOLOGIES SA (DBV.PA)

FR0010417345 - Common Stock

0.619  -0.01 (-1.28%)

Fundamental Rating

3

Taking everything into account, DBV scores 3 out of 10 in our fundamental rating. DBV was compared to 74 industry peers in the Biotechnology industry. DBV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, DBV is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

DBV had negative earnings in the past year.
DBV had a negative operating cash flow in the past year.
DBV had negative earnings in each of the past 5 years.
In the past 5 years DBV always reported negative operating cash flow.

1.2 Ratios

DBV has a worse Return On Assets (-63.70%) than 73.91% of its industry peers.
DBV's Return On Equity of -91.83% is on the low side compared to the rest of the industry. DBV is outperformed by 60.87% of its industry peers.
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROIC N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 95.70%, DBV belongs to the best of the industry, outperforming 91.30% of the companies in the same industry.
DBV's Gross Margin has been stable in the last couple of years.
DBV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%

More info and screens

4

2. Health

2.1 Basic Checks

DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.
DBV has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DBV has been increased compared to 5 years ago.
Compared to 1 year ago, DBV has a worse debt to assets ratio.

2.2 Solvency

DBV has an Altman-Z score of -1.93. This is a bad value and indicates that DBV is not financially healthy and even has some risk of bankruptcy.
DBV's Altman-Z score of -1.93 is in line compared to the rest of the industry. DBV outperforms 42.03% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that DBV is not too dependend on debt financing.
DBV has a Debt to Equity ratio of 0.09. This is in the better half of the industry: DBV outperforms 65.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -1.93
ROIC/WACCN/A
WACC6.72%

2.3 Liquidity

A Current Ratio of 3.29 indicates that DBV has no problem at all paying its short term obligations.
DBV has a better Current ratio (3.29) than 65.22% of its industry peers.
A Quick Ratio of 3.29 indicates that DBV has no problem at all paying its short term obligations.
DBV has a better Quick ratio (3.29) than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.29

More info and screens

6

3. Growth

3.1 Past

DBV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.56%, which is quite good.
DBV shows a strong growth in Revenue. In the last year, the Revenue has grown by 224.69%.
The Revenue has been growing slightly by 0.50% on average over the past years.
EPS 1Y (TTM)19.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.69%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%

3.2 Future

Based on estimates for the next years, DBV will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.96% on average per year.
Based on estimates for the next years, DBV will show a very strong growth in Revenue. The Revenue will grow by 88.16% on average per year.
EPS Next Y-36.93%
EPS Next 2Y2.12%
EPS Next 3Y59.71%
EPS Next 5Y14.97%
Revenue Next Year13.08%
Revenue Next 2Y478.54%
Revenue Next 3Y481.18%
Revenue Next 5Y88.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DBV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

DBV's earnings are expected to grow with 59.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.12%
EPS Next 3Y59.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DBV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA

EPA:DBV (12/24/2024, 7:00:00 PM)

0.619

-0.01 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2024-07-30/amc
Earnings (Next)N/A N/A
Inst Owners41.39%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap12.70M
Analysts82.86
Price Target5 (707.75%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.87%
Min EPS beat(2)-68.32%
Max EPS beat(2)10.57%
EPS beat(4)3
Avg EPS beat(4)13.32%
Min EPS beat(4)-68.32%
Max EPS beat(4)67%
EPS beat(8)6
Avg EPS beat(8)-1.96%
EPS beat(12)8
Avg EPS beat(12)1.52%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-20.42%
Min Revenue beat(2)-29.38%
Max Revenue beat(2)-11.45%
Revenue beat(4)2
Avg Revenue beat(4)690.02%
Min Revenue beat(4)-29.38%
Max Revenue beat(4)2602.52%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)47.92%
PT rev (3m)42.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.84
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-4.85
FCFYN/A
OCF(TTM)-4.73
OCFYN/A
SpS0.74
BVpS3.71
TBVpS3.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.7%
FCFM N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 15.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.29
Altman-Z -1.93
F-Score3
WACC6.72%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)11.98%
Cap/Sales(5y)19.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.69%
EPS Next Y-36.93%
EPS Next 2Y2.12%
EPS Next 3Y59.71%
EPS Next 5Y14.97%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%
Revenue Next Year13.08%
Revenue Next 2Y478.54%
Revenue Next 3Y481.18%
Revenue Next 5Y88.16%
EBIT growth 1Y20.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.39%
EBIT Next 3Y56.49%
EBIT Next 5YN/A
FCF growth 1Y-50.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.06%
OCF growth 3YN/A
OCF growth 5YN/A